We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

49 hedge funds and large institutions have $110M invested in Corbus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

38% more capital invested

Capital invested by funds: $79.4M → $110M (+$30.5M)

23% more funds holding

Funds holding: 4049 (+9)

0.98% more ownership

Funds ownership: 0%0.98% (+0.98%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

68% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $4.3M

Holders
49
Holders Change
+9
Holders Change %
+22.5%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
15
Reduced
9
Closed
9
Calls
$1.36M
Puts
$4.3M
Net Calls
-$2.93M
Net Calls Change
-$3.52M
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
1
Knoll Capital Management
Florida
$21.7M
CAM
2
Cormorant Asset Management
Massachusetts
$21.1M +$3.82M +16,666 +25%
PA
3
Perceptive Advisors
New York
$10.6M -$11.1M -48,367 -54%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10M -$49.7K -217 -0.5%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$9.33M +$8.44M +36,810 New
Millennium Management
6
Millennium Management
New York
$6.16M +$5.57M +24,305 New
BIT
7
BlackRock Institutional Trust
California
$4.61M +$2.52M +10,975 +152%
IA
8
IFP Advisors
Florida
$4.44M +$1.72M +7,517 +75%
RJFSA
9
Raymond James Financial Services Advisors
Florida
$3.23M +$176K +767 +6%
EI
10
EAM Investors
California
$2.73M +$2.46M +10,751 New
BBA
11
Baker Bros. Advisors
New York
$2.2M +$1.99M +8,671 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.46M +$3.67K +16 +0.3%
Creative Planning
13
Creative Planning
Kansas
$1.38M -$4.58K -20 -0.4%
CIBC Private Wealth Group
14
CIBC Private Wealth Group
Georgia
$1.21M +$1.1M +4,783 New
RJA
15
Raymond James & Associates
Florida
$1.18M +$1.07M +4,656 New
BFA
16
BlackRock Fund Advisors
California
$867K +$23.6K +103 +3%
EAM
17
EverPoint Asset Management
Connecticut
$867K +$784K +3,420 New
Russell Investments Group
18
Russell Investments Group
United Kingdom
$854K +$759K +3,312 New
Deutsche Bank
19
Deutsche Bank
Germany
$845K +$535K +2,333 +233%
Jane Street
20
Jane Street
New York
$572K +$397K +1,734 +333%
WC
21
Woodstock Corp
Massachusetts
$469K +$119K +519 +39%
Morgan Stanley
22
Morgan Stanley
New York
$467K +$193K +842 +84%
Barclays
23
Barclays
United Kingdom
$454K +$411K +1,793 New
HCM
24
Highbridge Capital Management
New York
$450K +$407K +1,775 New
Northern Trust
25
Northern Trust
Illinois
$383K -$917 -4 -0.3%

CRBP Hedge Fund Activity: Q4 2016 in Review

49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2016, worth a combined $110M — up 38% from $79.4M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CRBP positions and 9 closed out — a net gain of 10 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $8.44M. The largest seller was Perceptive Advisors, cutting an estimated $11.1M.

  • 49 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2016, up from 40 in Q3 2016.
  • Funds reported $110M of Corbus Pharmaceuticals stock for Q4 2016, up 38% quarter-over-quarter.
  • 19 funds opened new Corbus Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of +10 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2016 was Perceptive Advisors, an estimated $11.1M sold.

Based on aggregated 13F filings for Q4 2016.